Switzerland’s life science sector comprises 2,960 companies across biotechnology, medtech, digital health, pharma, investors, and supporting services. The 2026 Switzerland Life Science Trend Analysis, produced in partnership with Basel Area Business & Innovation and Life Science Zurich, highlights one of Europe’s most mature and well-capitalized life science ecosystems, with deep biotech roots, strong pharma presence, and a dynamic pipeline spanning oncology to anti-infectives.
The ecosystem includes 796 biotech companies, 330 medtech firms, 201 digital health companies, and 178 investors. Among biotech companies, therapeutics & diagnostics leads with 352 firms (44%), followed by R&D services (325 companies, 41%). The dominant modalities are small molecules (21%), antibodies (11%), and immunotherapy (11%), with anti-infectives (8%) and proteins (7%) also featuring prominently. Oncology accounts for the largest share of clinical assets (546), followed by neurology (166) and infectiology/parasitology (107). The pipeline spans all development stages — preclinical through Phase III — with 1,162 total assets available for out-licensing, of which 672 are therapeutics.
Geographically, Basel leads in biotech company count (232) and venture financing, while Zurich dominates in digital health (84 companies) and medtech (76 companies). Vaud and Geneva round out the top four cantons across all major categories.
Financing activity reflects a strongly recovering market. Private equity rounds for life science companies totalled $1,385M in 2024 and grew to $1,560M in 2025, with biotech companies specifically attracting $967M and $1,152M respectively. The standout period was 2025 H1, which recorded $856M across 22 rounds — the highest single half-year figure in the five-year dataset. The top 2025 private equity rounds were led by Windward Bio AG ($200M Series A), GlycoEra AG ($130M Series B), and Nuclidium AG ($99M Series B). On the M&A front, Switzerland’s most notable 2025 deals included the acquisition of Araris Biotech AG by Taiho Pharmaceutical for $1.14B and Vaximm AG by OSR Holdings for $845M, underscoring continued international appetite for Swiss biotech assets.
IPO activity has been measured but meaningful, with Galderma’s $2.611B listing in 2024 standing as the most significant public market event of the period, and Bioversys and MindMaze completing listings in 2025.
Looking ahead, Switzerland’s life science sector is supported by a rich late-stage pipeline, a highly diversified therapeutic modality landscape, and accelerating venture financing — positioning it as one of the premier life science hubs globally, with continued momentum in both therapeutics and digital health.
For more detailed insights, request a free Biotechgate demo.
Download the Switzerland Trend Analysis Report 2026